Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show
Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also highlighted that adding onvansertib to a standard Zytiga (by Janssen Biotech) and prednisone combination  led to treatment responses in patients carrying markers associated with resistance to Zytiga and other androgen receptor signaling (ARS) inhibitors. “Observing efficacy in patients that have tumors exhibiting known mechanisms of resistance to ARS inhibitor, Zytiga, suggests that onvansertib’s activity could extend to overcoming resistance to other ARS inhibitors, such as Xtandi and Erleada,” Mark Erlander, MD, Trovagene’s chief scientific officer, said in a press release. A poster with the data, “A phase II study of onvansertib in combinatio
Subscribe or to access all post and page content.